Nationwide germline whole genome sequencing of 198 consecutive pediatric cancer patients reveals a high incidence of cancer prone syndromes

Anna Byrjalsen(Copenhagen University Hospital), Thomas van Overeem Hansen(Copenhagen University Hospital), Ulrik Kristoffer Stoltze(Copenhagen University Hospital), Mana M. Mehrjouy(Copenhagen University Hospital), Nanna Moeller Barnkob(Technical University of Denmark), Lisa Lyngsie Hjalgrim(Copenhagen University Hospital), René Mathiasen(Copenhagen University Hospital), Charlotte Kvist Lautrup(Aalborg University Hospital), Pernille Axél Gregersen(Aarhus University Hospital), Henrik Hasle(Aarhus University Hospital), Peder Skov Wehner(Odense University Hospital), Ruta Tuckuviene(Aalborg University Hospital), Peter Wad Sackett(Technical University of Denmark), Adrian Otamendi Laspiur(Technical University of Denmark), Maria Rossing(Copenhagen University Hospital), Rasmus L. Marvig(Copenhagen University Hospital), Niels Tommerup(University of Copenhagen), Tina Elisabeth Olsen(Copenhagen University Hospital), David Scheie(Copenhagen University Hospital), Ramneek Gupta(Technical University of Denmark), Anne‐Marie Gerdes(Copenhagen University Hospital), Kjeld Schmiegelow(University of Copenhagen), Karin Wadt(Copenhagen University Hospital)
PLoS Genetics
December 17, 2020
Cited by 113Open Access
Full Text

Abstract

PURPOSE: Historically, cancer predisposition syndromes (CPSs) were rarely established for children with cancer. This nationwide, population-based study investigated how frequently children with cancer had or were likely to have a CPS. METHODS: Children (0-17 years) in Denmark with newly diagnosed cancer were invited to participate in whole-genome sequencing of germline DNA. Suspicion of CPS was assessed according to Jongmans'/McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG) criteria and familial cancer diagnoses were verified using population-based registries. RESULTS: 198 of 235 (84.3%) eligible patients participated, of whom 94/198 (47.5%) carried pathogenic variants (PVs) in a CPS gene or had clinical features indicating CPS. Twenty-nine of 198 (14.6%) patients harbored a CPS, of whom 21/198 (10.6%) harbored a childhood-onset and 9/198 (4.5%) an adult-onset CPS. In addition, 23/198 (11.6%) patients carried a PV associated with biallelic CPS. Seven of the 54 (12.9%) patients carried two or more variants in different CPS genes. Seventy of 198 (35.4%) patients fulfilled the Jongmans' and/or MIPOGG criteria indicating an underlying CPS, including two of the 9 (22.2%) patients with an adult-onset CPS versus 18 of the 21 (85.7%) patients with a childhood-onset CPS (p = 0.0022), eight of the additional 23 (34.8%) patients with a heterozygous PV associated with biallelic CPS, and 42 patients without PVs. Children with a central nervous system (CNS) tumor had family members with CNS tumors more frequently than patients with other cancers (11/44, p = 0.04), but 42 of 44 (95.5%) cases did not have a PV in a CPS gene. CONCLUSION: These results demonstrate the value of systematically screening pediatric cancer patients for CPSs and indicate that a higher proportion of childhood cancers may be linked to predisposing germline variants than previously supposed.


Related Papers

No related papers found

Powered by citation graph analysis